Table 2.

Multinomial logistic regression models showed the effect of daily PDN dose and disease activity on the physician’s decision to change the PDN dose, taking into account different definitions of active disease measured by ECLAM, the number of active BILAG domains and the lack of ECLAM or BILAG remission

	Unchanging	Tapering		Increasing		Discontinuing
		OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
Model 1	Ref.
PDN daily dose*	–	1.4 (1.3 to 1.5)	<0.001	1.0 (0.9 to 1.1)	0.863	1.0 (0.9 to 1.1)	0.644
ECLAM score†	–	1.1 (0.9 to 1.3)	0.299	1.6 (1.2 to 2.3)	0.004	1.0 (0.7 to 1.5)	0.826
Model 2	Ref.
PDN daily dose*	–	1.4 (1.3 to 1.5)	<0.001	1.0 (0.9 to 1.1)	0.386	1.0 (0.9 to 1.1)	0.586
ECLAM ≥1	–	1.1 (0.7 to 1.9)	0.607	1.8 (0.9 to 4.1)	0.145	0.8 (0.3 to 2.2)	0.698
Model 3	Ref.
PDN daily dose*	–	1.4 (1.3 to 1.5)	<0.001	1.0 (0.9 to 1.1)	0.543	1.1 (0.9 to 1.2)	0.408
Number of active BILAG domains	–	1.1 (0.8 to 1.3)	0.687	1.9 (1.3 to 3.0)	0.004	0.7 (0.3 to 1.2)	0.213
Model 4	Ref.
PDN daily dose*	–	1.4 (1.3 to 1.5)	<0.001	1.0 (0.9 to 1.1)	0.565	1.1 (0.9 to 1.2)	0.389
Active BILAG domains ≥1	–	0.9 (0.5 to 1.4)	0.599	2.5 (1.2 to 6.2)	0.025	0.4 (0.1 to 1.1)	0.085

*Per prednisone mg/day.

†Per ECLAM point.

BILAG, British Isles Lupus Assessment Group; ECLAM, European Consensus Lupus Activity Measurement; PDN, prednisone.